Gilead Sciences Bilan de santé
Santé financière contrôle des critères 4/6
Gilead Sciences possède un total de capitaux propres de $22.6B et une dette totale de $24.9B, ce qui porte son ratio d'endettement à 110.2%. Son actif total et son passif total sont $59.0B et de $36.4B. L'EBIT de Gilead Sciences est $11.8B ce qui fait que son ratio de couverture des intérêts 17.5. Elle dispose de liquidités et de placements à court terme de $9.6B.
Informations clés
110.25%
Ratio d'endettement
US$24.94b
Dette
| Ratio de couverture des intérêts | 17.5x |
| Argent liquide | US$9.61b |
| Fonds propres | US$22.62b |
| Total du passif | US$36.41b |
| Total des actifs | US$59.02b |
Mises à jour récentes de la santé financière
Recent updates
Gilead Sciences: Why I'm Tempted To Sell Ahead Of Q1 Earnings - But Won't
Apr 20
GILD: Oncology Deals And HIV Franchise Will Support Future Earnings
Analysts have raised the price target for Gilead Sciences to $180, citing recent upward revisions across Wall Street that reflect updated views on revenue growth, profitability and oncology deal activity. The core fair value estimate in this framework also remains at $180.GILD: HIV And PrEP Franchise Will Support Future Earnings And Margin Strength
Analysts have lifted the fair value estimate for Gilead Sciences to $180 from $159, citing higher modeled revenue growth, a slightly lower discount rate, and support from a wave of recent price target raises and positive initiation commentary on the company’s positioning and operating margins. Analyst Commentary Street research around Gilead Sciences has been active, with several bullish analysts updating their views and price targets in recent weeks.
GILD: HIV Franchise And Oncology Expansion Will Shape Bullish Long Term Outlook
The analyst fair value estimate for Gilead Sciences has moved from $132.57 to $157.43, with analysts pointing to stronger modeled revenue growth, slightly higher long term profit margins, and a higher future P/E multiple supported by recent price target hikes and positive views on the company's positioning in large cap biotech. Analyst Commentary Recent Street research on Gilead Sciences reflects a mix of optimism around growth drivers and caution around valuation and competitive risks.
GILD: Rich HIV Outlook Will Depend On Delivering High-Risk Oncology Acquisitions
Analysts have lifted their Gilead Sciences fair value estimate from $122.64 to $126.09 as they update models to reflect revised revenue growth and profit margin assumptions, along with a slightly higher discount rate and a modestly lower future P/E multiple, following a wave of higher Street price targets in recent weeks. Analyst Commentary Recent Street research around Gilead Sciences shows a mix of optimism and restraint.GILD: Elevated Future Expectations Will Hinge On Execution In Oncology
Gilead Sciences' updated analyst price target has moved sharply higher to $122.64 from $91.83, as analysts broadly lift their targets into the $140 to $170 range, citing steadier HIV franchise expectations, contributions from recent launches, and adjusted assumptions for expenses and oncology assets. Analyst Commentary Recent Street research shows a clear tilt toward higher valuation frameworks for Gilead Sciences, with several firms taking their targets into a broad US$140 to US$170 range.GILD: Extended HIV And PrEP Strength Will Support Steady Long-Term Earnings Power
Narrative Update: Gilead Sciences Analyst Price Target Shift Analysts have lifted their price targets on Gilead Sciences by as much as US$20, pointing to updated HIV franchise expectations, revised oncology and PrEP assumptions, and refreshed valuation approaches, even as some models incorporate higher IPR&D expenses and adjusted sales forecasts. Analyst Commentary Recent Street research around Gilead centers on two big themes in the models: the durability of the HIV franchise and the ramp in newer areas like PrEP and oncology, with several bullish analysts lifting price targets and reaffirming positive ratings.GILD: Extended HIV Franchise Strength Will Support Stronger Long-Term Earnings Power
Analysts have nudged their fair value estimate for Gilead Sciences up to $159 from $153, citing refreshed models that reflect updated HIV franchise expectations, oncology pipeline inputs, and evolving competitive readthroughs from peers in hepatitis and cell therapy. Analyst Commentary Recent Street research around Gilead Sciences has leaned constructive, with several bullish analysts refining their models and resetting price targets while pointing to HIV, oncology, and select liver and autoimmune assets as the key drivers they are watching.GILD: HIV PrEP Strength And Oncology Mixed Results Will Shape Outlook
Analysts have nudged their price targets on Gilead Sciences higher, generally toward the US$140 to US$145 range. They cite expectations for stronger HIV PrEP contributions from Yeztugo, a healthier outlook for the broader HIV portfolio including Biktarvy, and ongoing support from oncology and newer launches such as Livdelzi.GILD: Extended HIV Exclusivity Will Support Stronger Long-Term Earnings Power
Analysts have raised their fair value estimate for Gilead Sciences to $153 from $140, citing extended Biktarvy exclusivity, a stronger long term HIV growth outlook supported by Yeztugo and PrEP, and increasing conviction in oncology and broader large cap biopharma innovation potential. Analyst Commentary Bullish analysts continue to highlight Gilead as a core large cap biopharma holding, pointing to a healthier long term growth profile in HIV and a strengthening contribution from oncology.GILD: Extended HIV Franchise Will Offset Oncology And Policy Uncertainty Ahead
Analysts have nudged their blended price target for Gilead Sciences slightly lower by about $0.20 to the low-$130s, reflecting modestly higher discount rates and more conservative HIV and oncology growth and margin assumptions, even as they highlight extended Biktarvy exclusivity, encouraging Yeztugo uptake, and anito cel driven oncology optionality as key long term value drivers. Analyst Commentary Bullish analysts largely frame the recent price target tweaks as fine tuning within an increasingly constructive long term view, pointing to extended HIV cash flows, a strengthening PrEP opportunity, and optionality in oncology despite early stage competitive readouts.GILD: Extended Exclusivity And PrEP Opportunities Will Balance Ongoing Oncology And Policy Pressures
Analysts have modestly raised their price target for Gilead Sciences to $130.83 per share from $129.51. They cite the extended exclusivity period for Biktarvy and improved growth prospects in the HIV market as key drivers for the upward revision.GILD: HIV Business Strength And Patent Extension Will Balance Oncology Risks Ahead
Gilead Sciences' price target has been raised by analysts from $127 to $145. This reflects confidence in stable HIV business trends and improved execution, which offsets ongoing oncology and cell therapy challenges.Patent Extension And Policy Decisions Will Drive Access To Advanced Therapies
Gilead Sciences' analyst price target has increased from $126 to $127 per share. Analysts point to continued strong uptake of the Yeztugo launch in HIV and the recent Biktarvy patent extension as supporting factors, despite some pipeline setbacks.Global Healthcare Trends Will Expand Access To Advanced Therapies
Gilead Sciences saw its analyst price target increase from $124.91 to $126.31. Analysts cited improved sales forecasts for key HIV treatments and enhanced revenue growth expectations as the primary drivers of the upward revision.Global Healthcare Trends Will Expand Access To Advanced Therapies
Analysts remain constructive on Gilead Sciences, citing strong HIV franchise performance, positive FDA developments, and favorable regulatory tailwinds offsetting minor pipeline setbacks, resulting in an unchanged consensus price target of $124.37. Analyst Commentary Yeztugo’s FDA approval and clean label, strong clinical data, and convenient twice-yearly dosing are seen as key drivers for Gilead’s HIV franchise growth, with analysts generally positive on long-term adoption despite initial ramp expectations being slow and some cannibalization of Descovy anticipated.Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet?
Jul 27
Statutory Profit Doesn't Reflect How Good Gilead Sciences' (NASDAQ:GILD) Earnings Are
May 15Gilead Sciences Q1 Earnings Review: HIV Division Masks Underperformance
Apr 25New HIV, Livdelzi And CAR T Options Will Expand Reach
Gilead's innovation in HIV and oncology treatments supports revenue growth and market expansion in these therapeutic areas.Gilead: Growth Constraints Lead To Rating Downgrade Following 50% Rally
Mar 16Why Gilead Sciences Remains A Buy After A 40% Rally
Feb 27Analyse de la situation financière
Passif à court terme: Les actifs à court terme de GILD ( $18.3B ) dépassent ses passifs à court terme ( $11.8B ).
Passif à long terme: Les actifs à court terme de GILD ( $18.3B ) ne couvrent pas ses passifs à long terme ( $24.6B ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: Le ratio dette nette/capitaux propres de GILD ( 67.7% ) est considéré comme élevé.
Réduire la dette: Le ratio d'endettement de GILD a été réduit de 172.3% à 110.2% au cours des 5 dernières années.
Couverture de la dette: La dette de GILD est bien couverte par le flux de trésorerie opérationnel ( 40.2% ).
Couverture des intérêts: Les paiements d'intérêts de GILD sur sa dette sont bien couverts par l'EBIT ( 17.5 x couverture).
Bilan
Découvrir des entreprises saines
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/04/30 11:07 |
| Cours de l'action en fin de journée | 2026/04/29 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Gilead Sciences, Inc. est couverte par 66 analystes. 27 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| James Birchenough | Barclays |